21/04/2026
The study "𝗩𝗲𝗿𝘆 𝘀𝗵𝗼𝗿𝘁-𝘁𝗲𝗿𝗺 𝗺𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴 𝗼𝗳 𝗥𝗼𝗺𝗼𝘀𝗼𝘇𝘂𝗺𝗮𝗯 𝗹𝗼𝗻𝗴𝗶𝘁𝘂𝗱𝗶𝗻𝗮𝗹 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 𝗶𝗻 𝗮 𝗰𝗼𝗵𝗼𝗿𝘁 𝗼𝗳 𝗽𝗼𝘀𝘁𝗺𝗲𝗻𝗼𝗽𝗮𝘂𝘀𝗮𝗹 𝘄𝗼𝗺𝗲𝗻 𝗯𝘆 𝗺𝗲𝗮𝗻𝘀 𝗼𝗳 𝗥𝗮𝗱𝗶𝗼𝗳𝗿𝗲𝗾𝘂𝗲𝗻𝗰𝘆 𝗘𝗰𝗵𝗼𝗴𝗿𝗮𝗽𝗵𝗶𝗰 𝗠𝘂𝗹𝘁𝗶-𝗦𝗽𝗲𝗰𝘁𝗿𝗼𝗺𝗲𝘁𝗿𝘆 (𝗥𝗘𝗠𝗦) 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆", just published on Aging Clinical and Experimental Research (ACER) journal By Semeraro and colleagues, assessed for the first time the effectiveness of the Radiofrequency Echographic Multi Spectrometry (REMS) for very short-term monitoring of Romosozumab (RMZ) in postmenopausal women after only 6 months of treatment.
The complete study: https://www.echolightmedical.com/en/early-monitoring/